Roche Pharmaceutical Development and Sales Overview

YTD Sep 2022: Portfolio rejuvenation ongoing CHFM 46'684 +2% at CER -383 +2'397 -612 +217 -1,460 +621 -427 47'037 YTD Sep 2021 Dia base business Dia Pharma Ronapreve Actemra COVID-19 underlying sales sales sales business AHR erosion1 Fx YTD Sep 2022 YTD Sep 2022 values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion Diversification of Roche business YTD Sep 2017 CHF 39.4bn YTD Sep 2022 CHF 47.0bn AHR Diagnostics Other pharma Ophthalmology Infectious diseases Immunology AHR Oncology AHR Roche Neuroscience Hemophilia A 45 45

View entire presentation